Literature DB >> 19756775

An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project.

Kevin Yi-Lwern Yap1, En Yi Kuo, Jonathan Jun Jie Lee, Wai Keung Chui, Alexandre Chan.   

Abstract

PURPOSE: Cancer patients are at high risk of manifesting interactions from use of anticancer drugs (ACDs) and complementary and alternative medicines (CAMs). These interactions can result in sub-therapeutic effects or increased toxicities which may compromise the outcome of chemotherapy. It is important for practitioners to gain convenient access to ACD-CAM interaction information so as to make better-informed decisions in daily practice. This paper describes the creation of an oncology database (OncoRx) that documents ACD-CAM interactions, including traditional Chinese medicines (TCMs) that are commonly used for cancer treatment, prevention, and supportive care therapy.
METHODS: Information regarding ACDs, CAMs, and drug interactions were collated from 14 sources, inclusive of hardcopy and online resources, and input into a modified web server with a database engine and a programming interface using a combination of software and programming scripts.
RESULTS: OncoRx currently contains a total of 117 ACDs and 166 CAMs. Users are able to search for interactions based on various CAM uses: cancer treatment or prevention, immune-system-related, alopecia, nausea, and vomiting, peripheral neuropathy and pain, inflammation, fatigue, and non-cancer related. Pharmacokinetic data on ACDs and CAMs, characteristics of CAMs based on TCM principles, and drug interaction parameters such as effects, mechanisms, evidences, and proposed management plans, are shown in the search results.
CONCLUSION: OncoRx is an oncology database which detects ACD interactions. It is currently able to detect interactions with CAMs. It is hoped that OncoRx will serve as a useful resource to clinicians, educators, trainers, and students working in the oncology setting.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756775     DOI: 10.1007/s00520-009-0729-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  25 in total

Review 1.  Herb-drug interactions: interactions between kava and prescription medications.

Authors:  Rubin Bressler
Journal:  Geriatrics       Date:  2005-09

Review 2.  Complementary and alternative medicine during cancer treatment: beyond innocence.

Authors:  Metin Tascilar; Floris A de Jong; Jaap Verweij; Ron H J Mathijssen
Journal:  Oncologist       Date:  2006 Jul-Aug

Review 3.  Drug interactions between chemotherapeutic regimens and antiepileptics.

Authors:  Kevin Yi-Lwern Yap; Wai Keung Chui; Alexandre Chan
Journal:  Clin Ther       Date:  2008-08       Impact factor: 3.393

4.  Interaction of ginseng with phenelzine.

Authors:  B D Jones; A M Runikis
Journal:  J Clin Psychopharmacol       Date:  1987-06       Impact factor: 3.153

5.  Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH.

Authors:  R Ludwig; A Weirich; U Abel; W Hofmann; N Graf; M F Tournade
Journal:  Med Pediatr Oncol       Date:  1999-11

Review 6.  The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence.

Authors:  H R Shin; J Y Kim; T K Yun; G Morgan; H Vainio
Journal:  Cancer Causes Control       Date:  2000-07       Impact factor: 2.506

7.  Cat's claw inhibits TNFalpha production and scavenges free radicals: role in cytoprotection.

Authors:  M Sandoval; R M Charbonnet; N N Okuhama; J Roberts; Z Krenova; A M Trentacosti; M J Miller
Journal:  Free Radic Biol Med       Date:  2000-07-01       Impact factor: 7.376

8.  Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans.

Authors:  Bill J Gurley; Stephanie F Gardner; Martha A Hubbard; D Keith Williams; W Brooks Gentry; Yanyan Cui; Catharina Y W Ang
Journal:  Clin Pharmacol Ther       Date:  2002-09       Impact factor: 6.875

9.  Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.

Authors:  Bernard J Komoroski; Shimin Zhang; Hongbo Cai; J Matthew Hutzler; Reginald Frye; Timothy S Tracy; Stephen C Strom; Thomas Lehmann; Catharina Y W Ang; Yan Yan Cui; Raman Venkataramanan
Journal:  Drug Metab Dispos       Date:  2004-05       Impact factor: 3.922

10.  Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005.

Authors:  Heather S Boon; Folashade Olatunde; Suzanna M Zick
Journal:  BMC Womens Health       Date:  2007-03-30       Impact factor: 2.809

View more
  5 in total

Review 1.  Integrative oncology: managing cancer pain with complementary and alternative therapies.

Authors:  Alice Running; Teresa Seright
Journal:  Curr Pain Headache Rep       Date:  2012-08

Review 2.  Informatics confronts drug-drug interactions.

Authors:  Bethany Percha; Russ B Altman
Journal:  Trends Pharmacol Sci       Date:  2013-02-13       Impact factor: 14.819

3.  Oncologists' experiences of discussing complementary and alternative treatment options with their cancer patients. A qualitative analysis.

Authors:  Güthlin Corina; Holmberg Christine; Gudrun Klein
Journal:  Support Care Cancer       Date:  2016-04-14       Impact factor: 3.603

4.  Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin.

Authors:  Sabino Strippoli; Vito Lorusso; Anna Albano; Michele Guida
Journal:  BMC Complement Altern Med       Date:  2013-07-30       Impact factor: 3.659

5.  Knowledge and use of complementary therapies in a tertiary care hospital in France: A preliminary study.

Authors:  Mireille Michel-Cherqui; Rebecca Had-Bujon; Aurèlie Mongereau; Caroline Delannoy; Elodie Feliot; Florian Scotté; Marc Fischler
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.